Waiting for Reimbursement of New Medicines in Canada: It's Time for a Rethink

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.8, 2008-01, pp. : 629-632

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reimbursement in Canada: time to rethink the evidence?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 562, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Re-think on paying for medicines

By listed n.l.n.

International Journal of Pharmaceutical Medicine, Vol. 15, Iss. 1, 2001-02 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

The national reimbursement list in Hungary expanded by 126 new medicines in April

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 477, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

By Chabot Isabelle Rocchi Angela

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 837-845

Blackwell Publishing

Access to resources Recommend Favorite

External genital warts - time for a rethink

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 292, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite